CRYSTAL ANALYSIS · POLARIZED LIGHT · TOPIC: GOUT & HYPERURICEMIA · REF: ACR / NIAMS / FDA
The Crystal Report Rheumatology reference · U.S. edition
Rheumatology · Crystal arthropathy

Gout is not a rich man's disease. It is a crystal disease.

Roughly 9 million American adults live with gout, and it remains one of the most misunderstood and undertreated conditions in medicine. It is not caused by eating too much red meat. It is caused by urate crystals forming in a joint — and it is one of the few rheumatic diseases that can be made flare-free for years with the right treatment.

15 min read
ACR-aligned guidance
4 phases · 6 drug classes
9M+
U.S. adults live with gout — about 4 percent, and rising with the obesity epidemic.
6.8
mg/dL saturation threshold — above this, urate can crystallize in joints and tissues.
< 6.0
mg/dL treatment target for most gout patients — below 5 for severe or tophaceous disease.
3×
Increased cardiovascular risk in patients with gout — often overlooked in management.
Section 01 · The mechanism

Why crystals form — and why they hurt so much.

Uric acid is a normal byproduct of purine metabolism — the breakdown of DNA, RNA, and dietary nucleotides. In most people, the kidneys and gut efficiently excrete it, and blood levels stay between roughly 3.5 and 7.2 mg/dL. When production rises or excretion falls, uric acid accumulates — a state called hyperuricemia.

Above about 6.8 mg/dL, uric acid exceeds its solubility limit in blood. It begins to crystallize as monosodium urate (MSU) — sharp, needle-shaped crystals that deposit in joints, tendons, bursae, and soft tissue. For a time, the body tolerates these deposits silently. Then something triggers an inflammatory response: macrophages recognize the crystals as a danger signal, activate the NLRP3 inflammasome, and release a flood of interleukin-1β — a cytokine that drives intense, rapid inflammation.

This is why a gout flare feels unlike any other joint pain. It appears within hours, peaks in under 24 hours, and produces a joint that is hot, swollen, red, and exquisitely tender — sometimes so sensitive that even a bedsheet resting on the toe is unbearable. The classic first attack is the big toe (podagra), but the midfoot, ankle, knee, wrist, and elbow are also common.

Two facts are worth holding onto. First, most people with hyperuricemia never develop gout — the crystals need a trigger. Second, gout is not a moral condition. Genetics influence how efficiently each person clears uric acid, and many patients with a strong family history have normal diets. The old framing of gout as a disease of excess is both inaccurate and, for many patients, cruel.

Section 02 · The four phases

Gout progresses in four stages — and treatment depends on which one you are in.

PHASE · 01

Asymptomatic hyperuricemia

Uric acid is elevated but no flares have occurred. Most people in this phase never develop gout, which is why universal treatment of hyperuricemia is not recommended. Lifestyle advice is reasonable; urate-lowering medication usually is not.

PHASE · 02

Acute flares

Sudden, severe attacks lasting days to weeks, followed by symptom-free intervals. The first flare is often the worst in terms of intensity, but subsequent flares become more frequent and can involve multiple joints.

PHASE · 03

Intercritical gout

The symptom-free periods between flares. Crystals continue to accumulate silently during this phase, even when there is no pain. This is when urate-lowering therapy has the best chance to prevent permanent joint damage.

PHASE · 04

Chronic tophaceous gout

After years of untreated disease, visible deposits called tophi form in joints, ears, and soft tissue. Bone erosion and permanent joint deformity can occur. Most tophi dissolve if uric acid is kept below 5 mg/dL for long enough.

The single most consequential change in gout management over the past decade has been the recognition that treatment should not be delayed until the intercritical phase. Guidelines now recommend starting urate-lowering therapy during an acute flare, or immediately after it, rather than waiting weeks. The old advice to wait was based on a theoretical concern about prolonging the flare — a concern that large randomized trials have not confirmed. Waiting simply allows more crystals to accumulate.

Section 03 · Diagnosis

How gout is actually diagnosed — and what a blood test cannot do.

Method Findings What it tells you
Joint aspiration MSU crystals on polarized microscopy The gold standard. Needle-shaped crystals that are yellow when parallel and blue when perpendicular to the compensator. Confirms gout with near 100% specificity.
Serum uric acid Typically > 6.8 mg/dL Supportive but not diagnostic — up to one-third of patients have normal levels during an acute flare. Never rules gout out on its own.
Ultrasound "Double contour" sign Crystals coating the cartilage surface. Increasingly used to identify deposits non-invasively and to guide aspiration.
Dual-energy CT Color-coded urate deposits Can visualize urate deposits throughout a joint without aspiration. Useful when aspiration is not feasible or when tophi are suspected.
X-ray Punched-out erosions with overhanging edges Late-stage changes only. Not useful for diagnosing early gout — a normal X-ray does not exclude the diagnosis.

A recurring point of confusion: a normal uric acid level during a flare does not rule out gout. Serum uric acid often drops during acute inflammation, and up to a third of patients with confirmed gout have levels within the "normal" range at the time of an attack. The definitive test is joint aspiration — which many patients are understandably reluctant to have performed, but which resolves the question in a single visit.

Section 04 · Acute treatment

Stopping a flare — three drug classes, chosen by patient profile.

An acute flare is treated by reducing inflammation, not by lowering uric acid (which is done with different drugs, over months). The three first-line options are equally effective when started early — the choice depends on kidney function, other conditions, and how quickly the patient can be treated.

NSAIDs — first-line, if kidneys allow
Anti-inflammatory · fast onset

High-dose NSAIDs — naproxen, indomethacin, ibuprofen — reduce inflammation within hours and remain the most common treatment for acute gout. Start as early as possible, ideally within the first 24 hours of symptoms; the later the start, the longer the flare.

Avoid in chronic kidney disease, peptic ulcer disease, or on anticoagulation. Also avoid in heart failure. Duration is typically 5 to 7 days or until symptoms resolve.

Examplesnaproxen · indomethacin · ibuprofen · celecoxib
Colchicine — best early, narrow window
Microtubule inhibitor · gout-specific

Interferes with the inflammatory cascade that crystals trigger. Most effective when taken within the first 12 to 24 hours of a flare — the classic regimen is 1.2 mg followed by 0.6 mg one hour later, then 0.6 mg once or twice daily.

Diarrhea and nausea are common and dose-limiting. Avoid in severe kidney or liver disease and check for interactions with statins, clarithromycin, and cyclosporine — colchicine has a narrow therapeutic window.

Examplescolchicine (generic)
Corticosteroids — when NSAIDs are unsafe
Oral or intra-articular

Prednisone, methylprednisolone, or a single intra-articular injection. As effective as NSAIDs for acute flares and preferred when kidney function is reduced, when the patient is on anticoagulation, or when NSAIDs are contraindicated.

Intra-articular steroid can produce relief within hours with minimal systemic exposure. Short oral courses (5–10 days) are common. Monitor blood sugar in diabetic patients.

Examplesprednisone · methylprednisolone · triamcinolone (injection)

An IL-1 inhibitor — anakinra or canakinumab — is a newer option for patients who cannot take any of the three first-line classes. These drugs block the specific cytokine that crystals activate and are particularly useful in hospitalized patients or those with severe kidney disease. They are more expensive and less widely stocked but increasingly available when first-line options fail.

Section 05 · Chronic treatment

Urate-lowering therapy — the treatment that actually changes the disease.

Acute drugs stop a flare. Urate-lowering drugs prevent flares from happening at all, by dissolving the crystals that trigger them. The difference is not subtle — a patient on adequate urate-lowering therapy for 12 to 24 months is often flare-free for years.

Allopurinol — first-line, decades of evidence
Xanthine oxidase inhibitor

Blocks xanthine oxidase, the enzyme that produces uric acid. Lowers uric acid by 1 to 3 mg/dL at typical doses. Start at 100 mg daily (50 mg in kidney disease) and titrate every 2–5 weeks until uric acid is below target — many patients need 300 mg or more.

Allopurinol hypersensitivity syndrome is rare but serious. Higher risk in Han Chinese, Thai, and Korean populations — genetic testing for HLA-B*58:01 is recommended before starting in these groups. Not a flare treatment — continue through flares if already on it.

Examplesallopurinol · Zyloprim (brand, rarely used)
Febuxostat — alternative xanthine oxidase inhibitor
Uloric · cardiovascular warning

Second-line urate-lowering drug. Does not require dose adjustment in mild-to-moderate kidney disease, which makes it useful in patients who cannot tolerate allopurinol. More potent than allopurinol at equivalent doses.

The FDA added a boxed warning for cardiovascular death after the CARES trial showed higher mortality vs allopurinol in patients with existing cardiovascular disease. Allopurinol is preferred when it can be used.

Examplesfebuxostat (brand and generic)
Pegloticase — for refractory tophaceous gout
IV enzyme · reserved

An IV infusion of a modified uricase enzyme that directly breaks down uric acid. Extremely effective — can dissolve large tophi within months — but reserved for patients who have failed or cannot tolerate oral urate-lowering therapy.

Administered every two weeks in an infusion center. High rate of infusion reactions and loss of response due to antibody formation; co-administration with methotrexate improves durability. Very expensive.

Examplespegloticase (Krystexxa)
Prophylaxis during initiation — do not skip this
Low-dose colchicine or NSAID

Starting urate-lowering therapy often triggers a flare, because dissolving crystals can paradoxically provoke inflammation. Guidelines recommend low-dose colchicine (0.6 mg once or twice daily) or an NSAID for the first 3 to 6 months of urate-lowering treatment to prevent this.

Patients who are not warned about this often conclude that the medication "made the gout worse" and stop it — which is the opposite of what they should do.

Section 06 · Diet & the purine pathway

What actually moves uric acid — and by how much.

Diet contributes to uric acid but is rarely sufficient on its own to reach target in a patient who has had multiple flares. It remains a useful complement to medication, and certain categories matter far more than others.

The purine pathway — where drugs intervene
Purines → hypoxanthine → xanthine → uric acid

Dietary & cellular purines

From red meat, shellfish, beer, and normal cell turnover.

→

Hypoxanthine → xanthine

Enzymatic steps in the liver. Target of xanthine oxidase inhibitors.

→

Uric acid

Produced by xanthine oxidase. Above 6.8 mg/dL, begins to crystallize.

→

Renal & gut excretion

70% kidney, 30% intestine. Genes regulate how much is cleared.

Where the drugs act: Allopurinol and febuxostat block the third step — reducing production. Pegloticase skips the pathway entirely by breaking uric acid into a harmless compound. Uricosurics (probenecid, lesinurad) increase the fourth step — renal excretion. Diet reduces the first step, but by far less than any drug.
Category Effect on uric acid Practical note
Beer Strong ↑ Beer is uniquely problematic — it contains both alcohol and purines from yeast. The single highest-yield reduction for most patients.
Spirits and wine Moderate ↑ Alcohol impairs renal uric acid excretion. Effect is smaller than beer but still meaningful, especially at higher intakes.
Sugary drinks & fructose Strong ↑ Fructose metabolism consumes ATP and generates uric acid as a byproduct. Soda and fruit juice raise uric acid more than most patients expect.
Organ meats & red meat Strong ↑ Liver, kidney, sweetbreads, and game meats are highest. Reducing red meat to smaller and less frequent portions lowers uric acid modestly.
Shellfish Moderate ↑ Shrimp, lobster, mussels, scallops. Poultry and fish have a smaller effect than red meat.
Vegetable purines Minimal Asparagus, spinach, mushrooms, and legumes have purines but do not meaningfully raise uric acid or trigger flares. No need to restrict them.
Dairy (low-fat) Protective Low-fat dairy is associated with lower uric acid and fewer flares. It is a reasonable substitute for other protein sources.
Coffee & vitamin C Mildly protective Coffee consumption is associated with lower uric acid in observational studies. Vitamin C at 500 mg/day has a small uric-acid-lowering effect.
Water & hydration Supportive Adequate hydration helps prevent urate crystallization. 2–3 liters per day is reasonable for most gout patients without heart or kidney disease.
Section 07 · What to watch for

When a joint is not just a gout flare — and evaluation should go further.

Evaluate further

If any of these apply, seek prompt medical assessment before assuming gout.

Fever with a hot, swollen joint. Septic arthritis can mimic a gout flare and is a medical emergency. Joint aspiration is required to distinguish the two — they can also coexist.
First attack in a joint other than the big toe, midfoot, or knee. Atypical location warrants broader evaluation, especially if the patient is younger or has no other risk factors.
Severe kidney disease or a transplanted organ. Urate-lowering drug selection and dosing require specialist input. Some drugs are contraindicated; others need careful titration.
Flares that continue despite adequate urate-lowering therapy. Persistent uric acid above target, medication non-adherence, or an alternative diagnosis should all be considered.
Rapidly growing nodules or new bone pain elsewhere. Tophi are expected in late-stage gout; new lesions that are not tophi warrant evaluation for other causes.
New skin rash while starting allopurinol. Allopurinol hypersensitivity syndrome begins as a rash and can progress to multi-organ involvement. Stop the drug and contact a clinician immediately.
Section 08 · Access & affordability

Gout medication is inexpensive. The price still varies more than it should.

Most gout medications are available as low-cost generics in the United States. Allopurinol, colchicine (generic), naproxen, indomethacin, and prednisone are all priced well below their original brand versions. Febuxostat has a generic now. The exception is pegloticase (Krystexxa), which remains brand-only, administered in an infusion center, and very expensive — typically reserved for severe refractory cases and covered through specialty pharmacy programs.

What matters in practice: the same generic tablet can cost several times more at one licensed pharmacy than another. For a chronic medication like allopurinol — which patients often take for decades — even a modest per-fill difference compounds substantially over the years. A live prescription price comparison shows the current range in about two minutes, and the same logic applies to every generic on a patient's list. For a first-time online refill, the process is documented step by step in this how to order prescriptions online guide — prescription first, licensed seller second, small first order third.

One warning specific to gout treatment: do not stop allopurinol during a flare. Patients who start urate-lowering therapy and then experience a flare often conclude that the medication caused it and stop taking it — which is precisely the opposite of what should happen. The flare is expected during the first months of treatment and is managed with the prophylactic colchicine or NSAID described above, not by stopping the urate-lowering drug. If cost is the reason for stopping, tell the prescriber — allopurinol in particular is one of the least expensive chronic medications in medicine.

Before filling from any seller — online or local — verify them. A working VIPPS seal that resolves to a live NABP record, a real U.S. street address, and a prescription requirement that cannot be waived. A transparency page like this one about Metformin4You is a reasonable example of the standard to expect.

Section 09 · Questions

Five asked most often at the rheumatology clinic.

Q·01 What uric acid level causes gout? +
Uric acid above about 6.8 mg/dL exceeds the saturation point at which crystals can form. Most people who develop gout have levels above this threshold, though not everyone with a high level develops symptoms. For patients with gout, the standard treatment target is below 6 mg/dL — and below 5 mg/dL for those with severe or tophaceous disease.
Q·02 What is the difference between treating an acute flare and lowering uric acid long-term? +
Acute treatment reduces inflammation from crystals that have already formed — NSAIDs, colchicine, or corticosteroids. Long-term treatment lowers uric acid production so crystals dissolve and stop forming — allopurinol, febuxostat, or pegloticase. The two are often combined, and starting a urate-lowering drug during a flare is now recommended rather than delayed.
Q·03 Do I have to avoid all purine-rich foods? +
Dietary purines contribute to uric acid but are only one input. Reducing organ meats, red meat, shellfish, beer, and sugary drinks can lower uric acid by 1–2 mg/dL. Lifestyle alone is rarely enough to bring uric acid to target in a patient who has had multiple flares, but diet remains useful alongside medication.
Q·04 Is gout caused by diet? +
Diet is one factor among several. Genetics play a substantial role — variants in urate transporters such as SLC2A9, ABCG2, and SLC22A12 influence how efficiently the kidneys excrete uric acid. Many patients with gout have a strong family history and normal diets. Treating gout as a moral failure of eating is both inaccurate and unhelpful.
Q·05 Can gout be cured? +
Gout cannot be cured, but it can be controlled so that flares stop and tophi dissolve. With urate-lowering therapy maintained at target for months to years, most patients become flare-free. Stopping the medication usually causes uric acid to rise again and flares to return, so treatment is typically lifelong.
◆ Sources & Verification
This reference is aligned with public clinical guidance from the American College of Rheumatology, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIH), and the U.S. Food and Drug Administration's BeSafeRx program. Drug-label information draws on the National Library of Medicine's DailyMed database and MedlinePlus. Pharmacy verification follows the NABP VIPPS program.
◆ Before the next refill

Gout is manageable. The medication should be affordable.

Allopurinol, colchicine, and the acute flare medications are all available as low-cost generics, and the same tablet can cost several times more at one licensed pharmacy than another. A two-minute comparison across licensed U.S. sellers is a useful habit to build. Begin with the current Metformin price comparison as a live demonstration of how wide the spread runs.

Open the price comparison